Clinical Trial Update: EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) [Phase 2]

View source ↗

Summary

A Phase II single-arm trial (EPIK-P4) is evaluating the efficacy, safety, and pharmacokinetics of alpelisib in pediatric and adult patients with PIK3CA-related …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum

Drugs mentioned

• Alpelisib (alpelisib)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | Status: RECRUITING